FindTrial
Sign In

Tab Folic Acid 400 microgram orally daily plus local placentrex gel application efficacy in reversion of premalignant features using scrape cytology colour Doppler USG and FNAC

Use of Scrap Cytology Colour Doppler USG and FNAC for Screening and early detection of Cancer and assessing efficacy of Tab Folic Acid in reverting Premalignant Change - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107868
Enrollment
50
Registered
2026-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K132- Leukoplakia and other disturbancesof oral epithelium, including tongue

Interventions

Intervention1: Prospective Single arm open label design: Piolet study of Tablet Folic Acid 400 microgram daily orally plus local Placentrex gel application to see its efficacy in reverting premalignan

Sponsors

MLN Medical College Prayagraj
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically detectable premalignant oral lesions with cytological confirmation of dysplasia Any or combinations of the 8 nuclear features Karyohexis Karyolysis Nuclear Budding Multinucleation micronucleation prominent nucleolus Binucleation Nuclear Atypia Willing to comply with follow up and avoid areca nut and Tobacco

Exclusion criteria

Exclusion criteria: Malignant transformation at base line Pregnancy Lactation Known allergy to folic acid or Placentrex Severe systemic illness precluding follow up Prior treatment for the lesion in last 6 months

Design outcomes

Primary

MeasureTime frame
Efficacy of intervention Cytological Reversion Colour doppler finding reversion to normalTimepoint: At Base line 6months 12months and 6monthly up to 3 years—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Virendra Singh

MLN Medical College Prayagraj

singhv2003@gmail.com9044815554

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026